Story Stocks^®

Cardinal Health (CAH) is trading higher after delivering another strong earnings beat and issuing FY27 adjusted EPS guidance of $12.40-12.60, above the $12.11 consensus, reinforcing confidence in its ability to drive profit growth despite another revenue miss. The reaction reflects strong underlying execution, with Q4 adjusted operating earnings rising 30% yr/yr and adjusted EPS increasing 40%, while the FY27 outlook points to continued profit expansion across its major businesses.

• Pharmaceutical and Specialty Solutions remains the primary earnings engine, with Q4 revenue rising 6% and segment profit jumping 21% as brand and specialty products and the generics program supported profitability. For FY27, CAH expects 3-5% revenue growth and 8-11% segment profit growth, suggesting continued operating leverage in its largest business.
• Global Medical Products and Distribution revenue declined 2% in Q4, but segment profit increased sharply to $150 mln, helped materially by IEEPA tariff refunds. Importantly, CAH adjusts FY26 segment profit from $258 mln to a $158 mln underlying baseline after removing $100 mln of tariff refunds, making FY27 guidance of $200-220 mln equivalent to more than $50 mln of underlying profit improvement and providing a cleaner measure of the turnaround.
• NPHS, at-Home Solutions, and OptiFreight continue to become more meaningful contributors, with FY26 revenue rising 26% to $6.79 bln and segment profit increasing 37% to $707 mln. FY27 guidance calls for another 11-13% revenue increase and 15-18% segment profit growth, providing CAH with a faster-growing earnings stream outside traditional pharmaceutical distribution.
• The $12.40-12.60 FY27 adjusted EPS outlook represents 13-15% growth from a normalized FY26 EPS base of $10.95 rather than reported EPS of $11.26, which included a $0.31 benefit from IEEPA tariff refunds. This makes the outlook more impressive because CAH expects double-digit earnings growth after stripping out a nonrecurring benefit.
• CAH's priorities remain expanding Specialty, accelerating its higher-growth businesses, executing the GMPD Improvement Plan, and simplifying operations, giving management several levers for sustaining earnings growth even if overall revenue growth remains comparatively modest.

Briefing.com Analyst Insight

The strongest takeaway from CAH's report is that its earnings improvement is becoming broader and increasingly supported by multiple businesses rather than one primary driver. Pharmaceutical and Specialty Solutions continues to generate profit growth well ahead of revenue, while NPHS, at-Home Solutions, and OptiFreight are developing into meaningful growth contributors and the normalized GMPD outlook points to tangible progress in the Medical turnaround. Importantly, FY27 EPS guidance implies 13-15% growth after removing the FY26 tariff-refund benefit, making the outlook stronger than the headline comparison suggests. The key test in FY27 will be whether CAH can continue converting modest sales growth into double-digit earnings expansion through specialty growth, Medical improvement, and stronger contributions from its higher-growth businesses.